
Monopar Therapeutics Inc
NASDAQ:MNPR

Fundamental Analysis


Revenue & Expenses Breakdown
Monopar Therapeutics Inc
Balance Sheet Decomposition
Monopar Therapeutics Inc
Current Assets | 55.1m |
Cash & Short-Term Investments | 54.6m |
Other Current Assets | 523.5k |
Non-Current Assets | 9.1k |
PP&E | 9.1k |
Free Cash Flow Analysis
Monopar Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Monopar Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-17.7m
USD
|
Operating Income
|
-17.7m
USD
|
Other Expenses
|
1.1m
USD
|
Net Income
|
-16.6m
USD
|
MNPR Profitability Score
Profitability Due Diligence
Monopar Therapeutics Inc's profitability score is 49/100. The higher the profitability score, the more profitable the company is.

Score
Monopar Therapeutics Inc's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
MNPR Solvency Score
Solvency Due Diligence
Monopar Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Score
Monopar Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MNPR Price Targets Summary
Monopar Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
MNPR
is 59.16 USD
with a low forecast of 40.4 USD and a high forecast of 79.8 USD.
Dividends
Current shareholder yield for MNPR is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?